Accelerating the integration of China into the global development of innovative anticancer drugs.

[1]  Guanqiao Li,et al.  FDA decisions on new oncological drugs. , 2022, The Lancet. Oncology.

[2]  Guanqiao Li,et al.  Evolution of innovative drug R&D in China , 2022, Nature Reviews Drug Discovery.

[3]  Peiwen J. Ma,et al.  An overview of cancer drugs approved through expedited approval programs and orphan medicine designation globally between 2011 and 2020. , 2021, Drug discovery today.

[4]  H. Varmus,et al.  New York’s Polyethnic-1000: a regional initiative to understand how diverse ancestries influence the risk, progression, and treatment of cancers , 2021, Trends in Cancer.

[5]  Ning Li,et al.  Advances on anticancer new drugs in China and the USA in 2020: from ongoing trial to drug approval , 2021, Journal of the National Cancer Center.

[6]  Jiajv Chen,et al.  Institutional Framework for the Management of Human Genetic Resources in China. , 2021, Human Gene Therapy.

[7]  Toshio Shimizu,et al.  Guidelines for clinical evaluation of anti‐cancer drugs , 2021, Cancer science.

[8]  Guanqiao Li,et al.  Characteristics of expedited programmes for cancer drug approval in China , 2021, Nature Reviews Drug Discovery.

[9]  C. Gross,et al.  Evaluation of Drug Trials in High-, Middle-, and Low-Income Countries and Local Commercial Availability of Newly Approved Drugs , 2021, JAMA network open.

[10]  Yue Yang,et al.  The drug lag issue: a 20-year review of China , 2021, Investigational New Drugs.

[11]  F. Vicente,et al.  Academic collaborative models fostering the translation of physiological in vitro systems from basic research into drug discovery. , 2021, Drug discovery today.

[12]  Jie He,et al.  Cancer incidence and mortality in China, 2015 , 2020, Journal of the National Cancer Center.

[13]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[14]  M. Tohkin,et al.  Points to Consider for Implementation of the ICH E17 Guideline: Learning from Past Multiregional Clinical Trials in Japan , 2020, Clinical pharmacology and therapeutics.

[15]  Leping Yang,et al.  The burden of liver cirrhosis and underlying etiologies: results from the global burden of disease study 2017 , 2020, Aging.

[16]  Jie He,et al.  Changes in clinical trials of cancer drugs in mainland China over the decade 2009-18: a systematic review. , 2019, The Lancet. Oncology.

[17]  Asher Mullard.  Chinese biopharma starts feeding the global pipeline , 2017, Nature Reviews Drug Discovery.

[18]  T. Lang,et al.  Clinical Trials Have Gone Global: Is This a Good Thing? , 2012, PLoS medicine.

[19]  Charles B Cairns,et al.  Ethical and scientific implications of the globalization of clinical research. , 2009, The New England journal of medicine.

[20]  Hui Quan,et al.  Sample size considerations for Japanese patients in a multi‐regional trial based on MHLW guidance , 2009, Pharmaceutical statistics.